Drugs / NRL001
NRL001
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01175941 | Aug 2010 → Nov 2011 | — | Norgine | Completed | No outcome recorded |
| Phase 1 | NCT01099683 | Apr → Jul 2010 | — | Norgine | Completed | No outcome recorded |
| Phase 1 | NCT01099670 | Mar → Jun 2010 | — | Norgine | Completed | No outcome recorded |
| Phase 1 | NCT00857467 | Feb → Dec 2009 | — | Norgine | Completed | No outcome recorded |
| Phase 1 | NCT00850590 | Feb → Apr 2009 | — | Norgine | Completed | No outcome recorded |
| Phase 1 | NCT06593730 | Aug 2007 | — | Norgine | Completed | No outcome recorded |
| Phase 1 | NCT00893607 | Apr → Aug 2007 | — | Norgine | Completed | No outcome recorded |
| Phase 1 | NCT01406925 | Apr → May 2007 | — | Norgine | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NRL001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01099683 ↗ |
| Known as | 1R,2S-methoxamine | “0.5%w/w NRL001 (1R,2S-methoxamine) 1 mL, twice daily administration (morning and afternoon) for 14 days (study Days D1 to D14).” NCT06593730 ↗ |
| Known as | 1R,2S-methoxamine hydrochloride | “A randomised, controlled, crossover study to investigate the pharmacodynamics,
pharmacokinetics and safety of 1R,2S-methoxamine hydrochloride (NRL001) in
healthy elderly subjects.” PMID 24499494 ↗ Mar 20141“of 1R,2S-methoxamine hydrochloride (NRL001) on anal function in healthy” PMID 24499492 ↗ Mar 2014 |
| Action | Activate | “is a highly selective α1-adrenoceptor agonist” PMID 24499495 ↗ Mar 2014 |
| Modality | Small molecule | “The 1R,2S stereoisomer of methoxamine hydrochloride, NRL001, is a highly selective α1-adrenoceptor agonist being developed for the local treatment of non-structural faecal...” PMID 24499495 ↗ Mar 2014 |
| Route | Rectal | “NRL001 is administered at lower (5, 7.5 and 10 mg) or higher (10, 12.5 and 15 mg) doses in a slow release rectal suppository weighing either 1 g or 2 g.” NCT00850590 ↗ |